Provided by Tiger Trade Technology Pte. Ltd.

BioVie Inc

1.73
-0.0200-1.14%
Volume:103.67K
Turnover:177.82K
Market Cap:14.62M
PE:-0.57
High:1.81
Open:1.76
Low:1.69
Close:1.75
52wk High:3.79
52wk Low:0.8200
Shares:8.45M
Float Shares:8.41M
Volume Ratio:2.38
T/O Rate:1.23%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.0500
EPS(LYR):-3.0500
ROE:-150.76%
ROA:-79.06%
PB:1.42
PE(LYR):-0.57

Loading ...

BioVie Q4 EPS $(0.70) Up From $(1.42) YoY

Benzinga Earnings
·
Aug 13

BioVie FY26 Net Loss Widens to $22.1 Million; Operating Expenses Rise to $22.7 Million

Reuters
·
Aug 13

U.S. Stocks on the MOVE-Sutro Biopharma, Humacyte

Reuters
·
Aug 13

NASDAQ Trade Halt Volatility Trading Pause at 09:47 Am

Reuters
·
Aug 12

BioVie Posts Corporate Presentation Outlining Bezisterim and Biv201 Clinical Programs

Reuters
·
Aug 06

BioVie Says Phase 2 Sunrise-PD Trial Shows Bezisterim Improves Motor and Non-Motor Symptoms in Early Parkinson’s Disease

Reuters
·
Aug 06

BioVie - Bezisterim Well Tolerated with Safety Profile Comparable to Placebo

THOMSON REUTERS
·
Aug 06

BioVie - Bezisterim Shows Statistically Significant Improvements in Motor and Non-Motor Symptoms vs Placebo

THOMSON REUTERS
·
Aug 06

BioVie Announces Topline Results of Phase 2 Sunrise-Pd Trial of Bezisterim in Early Parkinson’s Disease

THOMSON REUTERS
·
Aug 06

BioVie - Bezisterim Reduces Biomarkers of Neurodegeneration and Inflammation

THOMSON REUTERS
·
Aug 06

BioVie - Phase 2 Trial Meets Prespecified Endpoints with Bezisterim Improving Inflammatory and Biological Markers

THOMSON REUTERS
·
Aug 06

BRIEF-Biovie Files To Offer Up To $300 Million In Securities - SEC Filing

Reuters
·
Jun 19

BioVie Files $300 Million Mixed Shelf

MT Newswires Live
·
Jun 19

BioVie files $300M mixed securities shelf

TIPRANKS
·
Jun 19

BioVie - Files to Offer up to $300 Mln in Securities - SEC Filing

THOMSON REUTERS
·
Jun 19

BioVie posts corporate presentation spotlighting bezisterim longevity-focused therapy pipeline

Reuters
·
Jun 02

BioVie to host live investor webinar with CEO presentation and Q&A

Reuters
·
May 27

Join BioVie’s Exclusive Live Investor Webinar and Q and A Session on June 2

GlobeNewswire
·
May 27

BioVie announces full enrollment of ADDRESS-LC trial of bezisterim

TIPRANKS
·
May 26

BioVie completes enrollment in Phase 2 long COVID trial of bezisterim, targets late summer 2026 data

Reuters
·
May 26